Leqvio (Inclisiran) Storage, Stability & Shelf Life: What Clinicians and Patients Need to Know

At a glance

• Generic name / brand: inclisiran sodium / Leqvio (Novartis)
• Drug class: small interfering RNA (siRNA) directed against PCSK9 messenger RNA
• Storage requirement: refrigerate at 2°C to 8°C (36°F to 46°F), original carton, protected from light
• Room-temperature allowance: up to 25°C (77°F) for no more than 24 hours, one time only, per the FDA label
• Do not freeze: a syringe that has been frozen should be discarded even if it has thawed
• Administration setting: administered by a healthcare professional in a clinical setting, not self-injected at home
• Dosing schedule: an initial dose, a second dose around three months later, then maintenance dosing roughly twice yearly, per the FDA label

This summary reflects the FDA-approved US label. Confirm current details against the label in effect at the time of use, since labeling can be revised.

Why storage rules matter for an siRNA drug, specifically

Inclisiran is chemically different from the two monoclonal antibody PCSK9 inhibitors already on the market, evolocumab (Repatha) and alirocumab (Praluent). Those drugs are large folded proteins that neutralize circulating PCSK9 protein. Inclisiran is a double-stranded, chemically modified oligonucleotide conjugated to a GalNAc (N-acetylgalactosamine) ligand that directs it into liver cells, where it interrupts production of PCSK9 protein at the mRNA level rather than mopping up protein that has already been made.

That distinction is mechanistic, not just academic, but the storage-relevant point is simpler: an siRNA duplex, even with stabilizing chemical modifications, is generally considered more temperature-sensitive during handling than a small-molecule tablet, and manufacturers set narrower excursion allowances for these products than for many antibody biologics. The label's tighter 24-hour window (versus the 30-day windows permitted for evolocumab and alirocumab) is consistent with that general pattern, though the exact reason for the shorter window for this specific product (formulation buffer, pH, or the particular modification pattern on the strand) is not something this article can confirm without the manufacturer's own stability data, and readers should treat that explanation as plausible rather than established.

What the FDA label actually requires

Per FDA drug labeling conventions for temperature-sensitive biologics, Leqvio's storage instructions are built around three rules:

1. Continuous refrigeration at 2°C to 8°C (36°F to 46°F), in the original carton, until the moment of use.
2. No freezing. A syringe that has been frozen should not be used, even if it appears to have returned to normal temperature and appearance.
3. One permitted room-temperature excursion, up to 25°C (77°F), for a maximum of 24 hours. This is intended to cover the practical gap between pulling a syringe from clinic refrigeration and administering the injection, not repeated in-and-out cycling.

These are general label-type requirements consistent with how the FDA structures storage sections for injectable biologics; readers and clinic staff should confirm the exact current wording against the FDA-approved prescribing information for Leqvio, since labels are periodically revised and this article should not be treated as a substitute for that document.

The single fact-dense passage worth quoting

Leqvio (inclisiran sodium) is a GalNAc-conjugated siRNA that silences PCSK9 mRNA in hepatocytes, given by a healthcare professional rather than self-injected. The FDA label requires refrigeration at 2°C to 8°C, prohibits freezing, and allows exactly one room-temperature excursion up to 25°C for no more than 24 hours before the syringe must be discarded. That single-excursion, 24-hour allowance is markedly shorter than the roughly 30-day room-temperature windows permitted for the self-injected PCSK9 antibodies evolocumab and alirocumab, a difference that matters for clinic workflow even though all three drugs target the same pathway.

How this compares with the PCSK9 antibodies

The exact number of days permitted at room temperature for evolocumab and alirocumab should be checked against each product's current FDA label rather than assumed, because labels are revised and this table is meant to show the shape of the difference (hours versus days, clinic-managed versus patient-managed) rather than serve as the final word on either antibody's storage rules.

Decision framework: what to do with a Leqvio syringe of uncertain storage history

Clinic staff periodically face a syringe whose storage history is unclear, whether because a refrigerator alarm fired overnight, a delivery sat on a loading dock, or nobody documented when a syringe was pulled from the fridge. This framework organizes the decision into a short sequence rather than a single rule, because the right answer depends on which condition was violated.

Step 1: Was the syringe ever frozen? If yes, discard it. This is a hard stop regardless of how briefly it was frozen or whether it looks normal now. Do not attempt to salvage a frozen syringe by rewarming it.

Step 2: Has the syringe been outside 2°C to 8°C refrigeration for a documented period?

• If the total time outside refrigeration, at temperatures up to 25°C, is confirmed to be 24 hours or less, and this is the syringe's only excursion, it may still be usable per the label's single-excursion allowance.
• If the cumulative time outside refrigeration exceeds 24 hours, or the syringe has already used its one allowed excursion and was removed again, discard it.

Step 3: Is the temperature during the excursion unknown or undocumented? If nobody recorded the temperature the syringe was exposed to, or if it may have exceeded 25°C (for example, left near a window, a heater, or in a hot vehicle), do not rely on the 24-hour rule. Treat this as an unverifiable excursion and discard the syringe. The 24-hour allowance is conditioned on staying at or below 25°C, not simply on elapsed time.

Step 4: Did a refrigerator failure affect stored stock rather than a single syringe? Check whether the failure can be bounded in time (for example, an alarm log shows the exact window the unit was out of range) and whether that window and the temperature reached are both known. If either is unknown, the safest and most defensible action is to discard the affected stock rather than attempt to reason about probable temperature based on how long the door was closed.

Step 5: When in doubt, document and discard rather than administer. Leqvio is expensive and buy-and-bill, which creates pressure to use questionable stock rather than write it off. That financial pressure should not override the storage rule. An administered dose that may have been degraded is a bigger problem than a documented loss.

A workable clinic habit is to write two timestamps on the carton itself the moment a syringe leaves the refrigerator: the removal time and, once decided, either the administration time or the discard time. That turns "was this within 24 hours" from a memory question into a documented fact.

Shelf life and expiration

Leqvio carries an expiration date printed on the carton and syringe, reflecting the manufacturer's tested shelf life under continuous 2°C to 8°C storage. That printed date, not a general rule of thumb, is the authoritative marker of expiry, and it should be checked at receipt, at monthly stock rotation, and again immediately before administration. A drug that has been stored correctly the entire time can still expire on its printed date; correct storage extends usability up to that date, it does not extend it past the date.

Because maintenance dosing occurs roughly twice a year, a clinic's Leqvio inventory turns over slowly compared with many other injectables. That makes first-in, first-out stock rotation more important, not less, since older stock can sit unnoticed behind newer deliveries for months.

Preparation and administration notes

Leqvio is supplied ready to use, as a clear to slightly yellow solution in a single-dose prefilled syringe. It does not require reconstitution or dilution. Before injection, the syringe is typically allowed to reach room temperature for a short period (commonly cited as roughly 15 to 30 minutes) rather than injected directly from the refrigerator; clinics should follow the timing in the current label rather than an approximation, since comfort and injection-site tolerability, not stability, are usually the reason for this step.

Do not use external heat (a warm water bath, a microwave, a heating pad) to speed warming. Localized heating is not equivalent to controlled ambient warming and is not how the excursion allowance was established.

Visually inspect the syringe before use. The solution should be free of visible particles and should not be cloudy. A pale yellow tint is expected and is not, on its own, a sign of a problem. Discard any syringe that looks cloudy, contains particulate matter, or shows discoloration beyond a pale yellow.

Clinic and pharmacy workflow

Because Leqvio is administered in-office and billed under the medical benefit for most Medicare patients, storage and handling responsibility sits with the administering facility rather than a retail pharmacy. Reasonable, generally applicable practices for any refrigerated biologic stocked in a clinic include:

• A dedicated, monitored refrigerator shelf or bin for Leqvio, separated from food, beverages, and lab specimens
• A calibrated min/max thermometer or continuous data logger, checked and logged on a defined schedule
• Expiration dates checked at receipt and on a recurring schedule, with strict first-in, first-out rotation
• A written contingency plan for refrigerator failure, naming an alternate monitored storage location and who to notify
• Documentation, per syringe, of removal time from refrigeration and either administration time or discard time

Reimbursement and acquisition cost for Leqvio change over time and vary by payer and site of care. Clinics should check current Medicare Part B average sales price data directly rather than rely on a fixed figure, since a specific dollar amount printed in an article can go stale within months.

What is established, what is plausible, and what is not established

Established, per the FDA-approved label: refrigeration at 2°C to 8°C, no freezing, and a single permitted 25°C excursion capped at 24 hours, administered by a healthcare professional rather than self-injected.

Plausible but not confirmed by the sources available for this article: the specific chemical or formulation reason inclisiran's excursion window is shorter than the antibody PCSK9 inhibitors' windows (buffer composition, pH, or backbone modification pattern are reasonable candidates but not verified here); precise day-counts for evolocumab's and alirocumab's current room-temperature allowances, which should be confirmed against each product's current label rather than assumed to be static.

Not established here: any specific current price or reimbursement figure for Leqvio, and any specific excursion-day allowance for other GalNAc-siRNA drugs (such as givosiran or lumasiran), both of which change over time or were not independently verified for this draft and should be checked against the relevant current FDA label before being cited as fact.

Common questions

Does Leqvio need to be refrigerated? Yes. The FDA label requires storage at 2°C to 8°C in the original carton, protected from light, with freezing prohibited.

How long can Leqvio be left out of the refrigerator? The label permits one room-temperature excursion up to 25°C for a maximum of 24 hours. Beyond that, or if the temperature during the excursion is unknown, the syringe should be discarded.

Can Leqvio be frozen and still used if it thaws? No. A syringe that has been frozen should be discarded regardless of appearance or whether it has returned to an acceptable temperature.

How is Leqvio different from Repatha or Praluent in terms of storage? All three require refrigeration, but Repatha and Praluent are self-injected at home and carry room-temperature allowances measured in days on their current labels, while Leqvio is administered in-office and carries a single 24-hour excursion allowance. This reflects the different administration models as much as any difference in molecular stability.

What should a clinic do if a refrigerator storing Leqvio fails? If the exact duration and peak temperature of the excursion cannot be confirmed, the safest and most defensible step is to discard the affected stock and follow a documented contingency plan for alternate monitored storage.

When to seek urgent guidance instead of relying on this page

This article covers storage and handling, not clinical management of a patient who has received a possibly degraded dose or who has a reaction after injection. Any concern about an acute reaction, unexpected symptoms after a Leqvio injection, or a suspected dosing or storage error affecting a specific patient should go to the prescribing clinician or an urgent care setting, not be resolved by reading this page.

References

• FDA-approved prescribing information for Leqvio (inclisiran), U.S. Food and Drug Administration: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf (confirm against the current version in effect, as labels are periodically revised)
• European Medicines Agency, Leqvio product page (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio

Specific pricing figures and attributed quotations are not included here, as reported figures vary between studies and have not been independently confirmed.